Rising Case Of Diseases In Newborn Is Progressing The Global Newborn Screening Market At 13.08% Of Cagr By 2027

Triton Market Research presents the Global Newborn Screening Market report segmented by Products (New-born screening instruments and New-born screening Reagents & Assay kits), Test type (Hearing screen test, Critical congenital heart disease (CCHD) Test, and Dry blood spot test), Technology (Hearing screen technology, Electrophoresis, Tandem Mass Spectrometry, Pulse Oximetry Technology, DNA based assays, and Enzymes & Immunoassay).

Triton Market Research depicts that the Global Newborn Screening Market is expected to propel at 13.08% of CAGR during the forecast period 2019-2027. The technological advancement, rising number of newborn disease cases, and supportive government policies regarding newborn health are majorly influencing the growth of the global newborn screening market across the globe. Conversely, conventional healthcare infrastructure in emerging countries and social barriers are key factors restraining the growth of the market.

The Global Newborn Screening Market is dominated by North America region, accounting for lion share in terms of revenue in the year 2018. The key factors primarily aiding the growth of the market in the region are supportive government policies. Moreover, proliferated funding in healthcare and R&D activities, along with the advanced and superior healthcare facilities is boosting the implementation of innovative healthcare ailments in the US and Canada, which is supplementing the market growth across the region.

According to WHO, the majority of the stillbirths are occurring in developing countries, yearly around 2.6 million, of which, 75% occur in South Asia and sub-Saharan Africa and rural areas of Asian and African regions include 60%. The key reasons for stillbirths are complication while childbirth, maternal infections during pregnancy, post-term pregnancy, maternal disorders, congenital abnormalities, and fetal growth restrictions. The majority of these deaths can be constrained post or prior birth, particularly with health measures and care during the first week of life. The newborn screening market has potential opportunities in the developing region due to the rising birth rate and premature birth in the emerging countries, which is creating demand for such diagnosis.

Major companies like Perkinelmer Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Trivitron Healthcare, Ge Healthcare, and others are adopting organic and inorganic strategies to gain a competitive edge in the global newborn screening market. For instance, On January 16, 2017, Bio-Rad acquired RainDance Technologies Inc. The company is involved in a broad array of biological reaction in the droplet, finding purpose in clinical research and life science, aiding the company’s expansion in next-generation sequencing application and intensifying their product portfolio. Also, On 10^th January 2016, NeoMass AAAC kit (CE Approved) was launched by Trivitron Healthcare to extend the newborn screening panel in India; the very first kit by the company for global development.